Effects of Neoadjuvant Chemotherapy on Multiple Cytokines in Patients with Tri-negative Breast Cancer

Abstract

The novel ET therapy is that doxorubicin and paclitaxel are used in neoadjuvant chemotherapy for tri-negative breast cancer (TNBC). The study mainly investigated the efficacy of ET therapy and its impact on tumor markers and cytokines. Firstly extracted from August 2017 to August 2020, 84 cases of TNBC patients were as experimental group in our hospital, and the patients were randomly divided into two groups, including the control group (42 cases) underwent conventional chemotherapy and observation group (42 cases) to accept ET neoadjuvant chemotherapy. To compare the therapeutic effect of two groups, levels of cytokines, tumor markers, and survival were detected. The results showed that the total efficiency of the control group was 80.95%, significantly lower than that of the observation group (95.24%), and the difference between the two groups was statisticallysignificant (P<0. 05). The survival rate of the control group was 78.57%, which was significantly lower than that of the observationgroup (95.24%). In addition, CEA, CA19-9, CA125 and VEGF of the control group were significantly higher than those of theobservation group (P<0. 05). Therefore, the ET therapy of neoadjuvant chemotherapy has an ideal effect on the treatment of TNBC,which can reduce the levels of tumor markers and cytokines, prolonging the survival rate of patients.